| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Envoy Medical, Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that the Nasdaq Hearings Panel (the "Panel) has granted the Company's request for continued listing on the Nasdaq Stock Market.
In granting the extension, the Panel considered several key developments, including Envoy Medical's recent equity capital raises and debt extinguishment, which combined together substantially increased the Company's stockholders' equity, and the FDA's recent approval of the Company's advancement to the final stage of the fully implanted Acclaim® cochlear implant clinical trial. The Company also noted increased investor momentum, with over 28 million shares now outstanding, and a noticeable increase in trading volume since the trial expansion announcement.
The Panel granted Envoy Medical until February 23, 2026, to demonstrate full compliance with Nasdaq Listing Rule 5550(b)(2). This deadline reflects the full extent of the Panel's discretionary authority to allow continued listing while the Company remains non-compliant.
Envoy Medical will continue to provide timely updates to Nasdaq and the public regarding its compliance progress.
Posted In: COCH
